News

On December 4, 2025, Corina® Intrauterine Drug-Eluting Stent received market approval from the Malaysia Medical Device Authority (MDA).

In November 2025, Yipurun made a strong debut at MEDICA, the world’s leading medical technology exhibition, held at the Düsseldorf Exhibition Center, Germany, showcasing its innovative drug–device combination product, Corina® (Intrauterine Drug Eluting Stent).

In October 2025, at the 34th Annual Meeting of the European Society of Gynaecological Endoscopy (ESGE), Professor Feng Limin from Beijing Tiantan Hospital, Capital Medical University, presented extensive real-world clinical data on the application of Corina® (Intrauterine Drug Eluting Stent) based on a large number of cases from China.

In April 2025, Professor Zhang Luping from the Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, was invited to speak at the World Congress of the International Federation of Fertility Societies (IFFS) held in Tokyo, Japan.

In late April 2025, at the Global Congress on Endometriosis and Uterine Diseases (SEUD) held in Prague, Czech Republic, Professor Feng Limin from the Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, presented the core clinical technology behind Corina® (Intrauterine Drug Eluting Stent) to an international audience of gynecology specialists.

On September 24th, a grand gathering that brought together the essence of technological innovation and showcased the brilliance of transformation achievements

SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who undergo transcervical resection of adhesions (TCRA). The approval for this indication is based on a randomized controlled clinical trial that

“BISORB®Drug-Eluting Sinus Absorbable Stent System Gains International Recognition Again, Approved for Registration in Colombia On May 31, 2024, Puyi (Shanghai) Biotech Co., Ltd. achieved another breakthrough in the field of medical innovation by obtaining approval from the Colombian authorities for the marketing of its Xiangtong Fully Biodegradable Drug-Eluting Sinus Stent System. The registered name of the product in

On February 6, 2024, Corina® Intrauterine Drug-Eluting Stent, independently designed and developed by Yipurun (Shanghai) Biotechnology Co., Ltd., received its market approval from the Singapore Health Sciences Authority (HSA).
To date, Corina® has been approved in 10 overseas countries, including seven Asia-Pacific markets—Singapore, Thailand, the Philippines, Indonesia, Vietnam, Malaysia, and New Zealand—and three Latin American countries: Colombia, Peru, and Bolivia.